Optimal two-stage randomized multinomial designs for phase ii oncology trials

Journal of Biopharmaceutical Statistics

Volumn 19, Issue 3, 2009, Pages 485-493

  Sun, Linda Z ^a   Chen, Cong ^a   Patel, Kamlesh ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Pi Square ^*  (United States)

Author keywords

Multinomial; Oncology trials; Progression; Randomized; Response

Indexed keywords

ALGORITHM; ANTINEOPLASTIC ACTIVITY; ARTICLE; BAYES THEOREM; ERROR; EXPERIMENTAL DESIGN; EXPERIMENTAL THERAPY; HUMAN; METHODOLOGY; NULL HYPOTHESIS; ONCOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; TREATMENT RESPONSE; BIOASSAY; DECISION SUPPORT SYSTEM; PHASE 2 CLINICAL TRIAL;

ALGORITHMS; CLINICAL TRIALS, PHASE II AS TOPIC; DECISION SUPPORT TECHNIQUES; ENDPOINT DETERMINATION; HUMANS; MEDICAL ONCOLOGY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 67651017817     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543400902802417     Document Type: Article

References (14)

1. Fleming, T. R. (1982). One sample multiple testing procedure for phase II clinical trials. Biometrics 38:143-151.
2. Freidlin, B. et al. (2002). Correspondence-multinomial Phase II trial designs. J. Clin. Oncol. 20:599-599
3. Gehan, E. A. (1961). The determination of the number of patients required in a follow-up trial of a new chemotherapeutic agent. J. Chronic Disease 13:346-353.
4. Goffin, J., Tu, D. (2007). Phase II stopping rules employing response rates and early progression. American Society of Clinical Oncology Annual Meeting. Poster.
5. Jennison, C., Turnbull, B. (1993). Group Sequential Methods with Applications to Clinical Trials. Chapman & Hall.
6. Simon, R. (1989). Optimal two-stage designs for Phase II clinical trials. Contr. Clin. Trials 10:1-10.
7. Simon, R., Wittes, R. E., Ellenberg, S. S. (1985). Randomized Phase II clinical trials. Cancer Treatment Reports 69:1375-1381.
8. Simon, R., Thall, P. F., Ellenberg, S. S. (1994). New designs for the selection of treatments to be tested in randomized clinical trials. Stat. Med. 13:417-429.
9. Stallard, N., Thall, P. F., Whitehead, J. (1999). Decision theoretic designs for Phase II clinical trials with multiple outcomes. Biometrics 55:971-977.
10. Thall, P. F., Sung, H. (1998). Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials. Stat. Med. 17:1563-1580.
11. Thall, P. F., Cheng, S. (1999). Treatment comparisons based on two-dimensional safety and efficacy alternatives in oncology trials. Biometrics 55:746-753.
12. Thall, P. F., Simon, R., Ellenberg, S. S. (1989). A two-stage design for choosing among several experimental treatments and a control in clinical trials. Biometrics 45:537-547.
13. Thall, P. F., Simon, R. M., Estey, E. H. (1995). Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Stat. Med. 14:357-379.
14. Zee, B., Melnychuk, D., Dancey, J., Eisenhaver, E. (1999). Multinomial Phase II cancer trials incorporating response and early progression. J. Biopharm. Stat. 9(2):351-363.